Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 7/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.32 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.30 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25123571 | 0.90 | NTRK1 (0.39) | NTRK1PDK2POLBMAPTMEN1 | |
| SCHEMBL25123543 | 0.90 | NTRK1 (0.39) | NTRK1PDK2POLBMAPTMEN1 | |
| SCHEMBL29341575 | 0.82 | NTRK1 (0.38) | NTRK1POLBMAPTMEN1KMT2A | |
| SCHEMBL25107960 | 0.81 | NTRK1 (0.36) | NTRK1POLBMAPTMEN1KMT2A | |
| SCHEMBL25109676 | 0.80 | NTRK1 (0.36) | NTRK1POLBMAPTMEN1KMT2A | |
| SCHEMBL25109273 | 0.80 | NTRK1 (0.35) | NTRK1POLBMAPTMEN1KMT2A | |
| SCHEMBL25108628 | 0.79 | NTRK1 (0.36) | NTRK1POLBMAPTMEN1KMT2A | |
| SCHEMBL25107929 | 0.79 | NTRK1 (0.36) | NTRK1POLBMAPTMEN1KMT2A | |
| SCHEMBL31709014 | 0.79 | NTRK1 (0.36) | NTRK1POLBMAPTMEN1KMT2A | |
| SCHEMBL30228348 | 0.79 | NTRK1 (0.36) | NTRK1POLBMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542278-B1 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11542278-B1 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542278-B1 | Heteroaromatic macrocyclic ether chemotherapeutic agents | CYP2C8, ABCB1, CYP3A43 | NTRK1 4065/4885PDK2 652/4885POLB 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.